Constipation – Pipeline Review, Q1 2011
Constipation - Pipeline Review, Q1 2011
Reference Code: GMDHC272IDB
Publication Date: March 2011
Constipation – Pipeline Review, Q1 2011 GMDHC272IDB / Pub March 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
Page(1)
Constipation – Pipeline Review, Q1 2011
Ta b le o f Co n te n ts
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Constipation Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Constipation 9
Constipation Therapeutics under Development by Companies 11
Constipation Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Constipation Therapeutics - Products under Development by Companies 19
Constipation Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Constipation Therapeutics Development 22
Abbott Laboratories 22
Alkermes, Inc. 22
Samyang Corporation 23
Dong-A Pharmaceutical Co., Ltd. 23
Ono Pharmaceutical Co., Ltd. 24
Pfizer Inc. 24
Progenics Pharmaceuticals, Inc. 25
Shire Plc 25
AlbireoPharma 27
Callisto Pharmaceuticals, Inc. 27
Cosmo Pharmaceuticals S.p.A 28
Adolor Corp. 28
ARYx Therapeutics 29
Theravance, Inc. 29
Sucampo Pharmaceuticals, Inc. 30
Ironwood Pharmaceuticals, Inc. 30
KYORIN Pharmaceutical Co., Ltd. 31
Braintree Laboratories, Inc. 31
S.L.A. Pharma AG 32
AstraZeneca AB 32
Norgine B.V 33
MicroDose Therapeutx, Inc. 33
Beech Tree Labs, Inc. 34
SK Bio-Pharmaceuticals 34
Constipation - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Constipation – Pipeline Review, Q1 2011 GMDHC272IDB / Pub March 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Constipation – Pipeline Review, Q1 2011
Assessment by Combination Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 40
Late Stage Drug Profiles – Companies 42
Oral NKTR-118 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Resolor - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Linaclotide - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Amitiza - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Subcutaneous Methylnaltrexone - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Oral Methylnaltrexone - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Methylnaltrexone - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
MOA728 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Late Stage Drug Profiles – Universities/Institutes 53
naloxone hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Methylnaltrexone - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Constipation - Featured News 55
Nov 30, 2010: Sucampo's Lubiprostone Successfully Completes Long-Term Phase III Safety Trial In Chronic Idiopathic Constipation 55
Nov 16, 2010: Progenics Reports Initiation Of Phase II Clinical Trial Of Subcutaneous Methylnaltrexone In Japan By Ono Pharmaceutical
56
Constipation – Pipeline Review, Q1 2011 GMDHC272IDB / Pub March 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3)
Constipation – Pipeline Review, Q1 2011
Nov 01, 2010: Ironwood And Forest Announce Positive Linaclotide Results From Second Phase III Trial In Irritable Bowel Syndrome With
Constipation 56
Oct 21, 2010: Theravance Announces Positive Results from Phase I and Phase II Clinical Studies with TD-1211 in Development for
Opioid-Induced Constipation 58
Oct 19, 2010: Adolor Initiates Phase II Opioid-Induced Constipation Study Of ADL5945 59
Oct 12, 2010: Albireo Announces Positive Results From Phase IIb Trial Of A3309 In Patients With Chronic Idiopathic Constipation 60
Oct 07, 2010: Sucampo Submits Marketing Application To Japanese Regulatory Authorities For Amitiza 61
Oct 06, 2010: Synergy Announces Positive Phase IIa Results Of Plecanatide To Treat Chronic Constipation 61
Sep 21, 2010: Progenics Completes Subcutaneous Methylnaltrexone Safety Study In Chronic Non-Malignant Pain Patients 62
Sep 13, 2010: Ironwood And Forest Announce Positive Linaclotide Results From Phase III Trial In Patients With Irritable Bowel Syndrome
With Constipation 63
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 67
Contact Us 67
Disclaimer 67
Constipation – Pipeline Review, Q1 2011 GMDHC272IDB / Pub March 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied